Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CXCR2 | P25025 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368026 | 0.91 | CXCR2 (0.50) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3368009 | 0.88 | TSHR (0.46) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3368363 | 0.88 | TSHR (0.50) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL13437612 | 0.86 | CXCR2 (0.48) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3368711 | 0.86 | CXCR2 (0.56) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3367397 | 0.85 | ALDH1A1 (0.46) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3367935 | 0.84 | TSHR (0.44) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL3365614 | 0.84 | ALDH1A1 (0.46) | TSHRALDH1A1CXCR2TP53KDM4E | |
| SCHEMBL13114635 | 0.83 | ALDH1A1 (0.46) | TSHRALDH1A1CXCR2KDM4EMAPT | |
| SCHEMBL3368359 | 0.83 | CXCR2 (0.59) | TSHRALDH1A1CXCR2TP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094696-B1 | 5-SULFANYLMETHYL-[1,2,4] TRIAZOL[1, 5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS | NOVARTIS AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-20100069407-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069407-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | TSHR 2129/4885ALDH1A1 931/4885CXCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.